{'fraction_non_alphanumeric': 0.027659574468085105, 'fraction_numerical': 0.031914893617021274, 'mean_word_length': 5.970370370370371, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In‐vitro evidence for the regulation of 17,20‐lyase activity by cytochrome b5 in adrenocortical adenomas from patients with Cushing's syndrome

OBJECTIVE The electron transfer system molecules, NADPH‐cytochrome P450 reductase (Red) and cytochrome b5 (bS) are known to increase the relative activity of 17,20‐lyase to 17α‐hydroxylase in vitro. Consistent with this hypothesis, we have reported recently that adrenocortical adenomas from patients with Cushing's syndrome that produced exceptionally high concentrations of androgens also contained more b5 mRNA as well as greater 17,20‐lyase activity than adenomas that produced low concentrations of androgens. This finding was suggestive but inconclusive in linking b5 functionally to this difference in adenoma 17,20‐lyase activity. In the present study, we have extended this finding by examining the effect of bS on microsomal 17,20‐lyase activity using an antibody against cytochrome b5.